Influenza A virus conserved internal protein epitopes (IAV conserved epitopes)

Influenza A virus conserved internal protein epitopes are peptide sequences derived from stable viral proteins such as Nucleoprotein (NP), Matrix protein 1 (M1), and Polymerase Basic protein 1 (PB1) (UniProt: P03466, P03485). Unlike surface glycoproteins like Hemagglutinin, these internal proteins are highly conserved across different influenza subtypes, including H1N1, H3N2, and H5N1 (PubMed: 24931151). These epitopes are processed and presented on the cell surface by Human Leukocyte Antigen (HLA) Class I and Class II molecules to CD8+ and CD4+ T cells, respectively (PubMed: 28916518). Presentation to CD8+ T cells leads to the destruction of infected cells, while presentation to CD4+ T cells coordinates the broader immune response and supports B-cell activity (PubMed: 22685329). These epitopes serve as the primary targets for universal influenza vaccines designed to provide cross-protective immunity against drifting seasonal strains and emerging pandemic threats (PubMed: 32163571). Clinical candidates like FLU-v and Multimeric-001 (M-001) utilize these conserved sequences to induce long-lasting cellular memory (PubMed: 29453264). While they may not provide sterilizing immunity, they significantly reduce viral shedding and clinical symptom severity in infected individuals (ClinicalTrials.gov: NCT03282240).

Other names

Conserved influenza antigensIAV T-cell epitopesUniversal influenza vaccine targetsInternal viral proteins (NP, M1, PB1)

Induction of cross-reactive cellular immune responses by activating CD4+ and CD8+ T cells against conserved internal viral antigens.